메토트렉세이트 의약품 시장 : 적응증별, 약제 유형별, 제형별, 투여 경로별, 유통 채널별, 세계 예측(2024-2032년)

Global Methotrexate Drugs Market will depict 3.1% CAGR from 2024 to 2032, credited to the growing geriatric population. According to the WHO, the proportion of the global population over 60 years old is expected to almost double, rising from 12% in 2015 to 22% by 2050. Additionally, by 2050, 80% of older individuals will reside in low- and middle-income countries.

As people age, they become more susceptible to chronic conditions such as cancer and autoimmune diseases, including rheumatoid arthritis and psoriasis, which are commonly treated with methotrexate. The increasing number of older adults, particularly in low- and middle-income countries, drives the demand for effective treatment options. Additionally, advancements in healthcare infrastructure and improved access to medical care for the elderly further boost the adoption of methotrexate drugs, supporting market expansion.

The overall Methotrexate Drugs Industry is categorized based on indication, drug type, drug form, route of administration, distribution channel, and region.

The generic drug segment will experience significant growth from 2024 to 2032. Generic methotrexate drugs offer cost-effective treatment options, increasing accessibility and affordability for patients. The demand for generic drugs is propelled by their equivalence in efficacy and safety to branded drugs, in line with lower costs, driving market expansion.

Retail pharmacies will play a crucial role in the distribution of methotrexate drugs during 2024-2032. Retail pharmacies provide convenient access to medications, ensuring patients can easily obtain their prescriptions. The extensive reach of retail pharmacies, in tandem with personalized customer service, enhances patient adherence to methotrexate treatments, bolstering market growth.

Asia Pacific methotrexate drugs market is set to achieve notable gains throughout 2024-2032, attributed to improving healthcare infrastructure, rising investments in medical research, and a high prevalence of chronic diseases such as cancer and autoimmune disorders. Strong regulatory frameworks ensure the quality and safety of pharmaceutical products, fostering widespread use. Additionally, government support for healthcare initiatives and the presence of leading pharmaceutical companies drive innovation and production, contributing to the robust growth of the methotrexate market in the region.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer
    • 3.2.1.2 Ongoing research and development using methotrexate drugs
    • 3.2.1.3 Rising technological advancements and demand for personalized medicine
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Limited reimbursement and coverage policies
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Clinical trials on methotrexate
• 3.7 Pricing analysis, 2023
  • 3.7.1 By region
  • 3.7.2 By key player
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Psoriasis
• 5.3 Rheumatoid arthritis
• 5.4 Cancer
• 5.5 Other indications

Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Branded
• 6.3 Generic

Chapter 7 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Tablet
• 7.3 Liquid
• 7.4 Injectable

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Subcutaneous
• 8.4 Intramuscular
• 8.5 Intravenous

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Accord Healthcare
• 11.2 Amneal Pharmaceuticals LLC
• 11.3 Apotex Inc.
• 11.4 Cipla Limited
• 11.5 Dr. Reddy's Laboratories Ltd.
• 11.6 Hikma Pharmaceuticals PLC
• 11.7 Intas Pharmaceuticals Ltd.
• 11.8 Lupin Limited
• 11.9 Merck KGaA
• 11.10 Novartis AG
• 11.11 Pfizer Inc.
• 11.12 Sun Pharmaceutical Industries Ltd.
• 11.13 Teva Pharmaceutical Industries Ltd.
• 11.14 Viatris Inc.
• 11.15 Zydus Cadila